XVIII International HIV Drug Resistance Workshop
Selected Slide Presentations Click on the links below to view presentations.
Persistence, Reservoirs and Elimination Strategies
Roles of NFAT, cell division and IL-7 stimulation on HIV-1 reactivation from latency in primary memory T-cells
Alberto Bosque; University of Utah, USA
SJ23B, a jatrophane diterpene, induces HIV receptors downregulation and HIV transcription through activation of Ras-MEK pathway and classical PKCs
Jose Alcami; Instituto de Salud Carlos III, Spain
Longitudinal dynamics of persistent viremia in elite controller patients versus patients on suppressive therapy
Sarah Palmer; Swedish Institute for Infectious Disease Control, Karolinska Institute, Sweden
HIV-specific CD4+ T-cells may contribute to viral persistence in HIV-infected elite controllers
Peter Hunt; University of California, San Francisco, USA
Markers of cellular immune activation do not correlate with levels of residual viremia in patients on long-term suppressive antiretroviral therapy
Francesca Cossarini; National Cancer Institute, National Institutes of Health, USA
No evolution of HIV-1 total DNA and 2-LTR circles after 24 weeks of raltegravir-containing regimen: a substudy of randomized EASIER-ANRS 138 trial
Constance Delaugerre; Saint Louis Hospital, France
Antiretroviral intensification does not reduce persistent HIV-1 viremia on therapy
Frank Maldarelli; NCI Drug Resistance Program, USA
Resistance to Entry Inhibitors
Different mechanisms of HIV-1 inhibition by CCR5 agonists/antagonists (maraviroc, TAK-779 and PSC-RANTES) are linked to different drug resistance mechanisms
Eric Arts; Case Western Reserve University, USA
Estimating evolutionary pathways to CXCR4 usage from cross-sectional data
Alexander Thielen; Max-Planck Institute for Informatics, Germany
Modification of the CCR5 binding site by mutations in gp120 influence drug susceptibility and viral infectivity in one subject with clinical resistance to vicriviroc
John Howe; Schering?Plough Research Institute, USA
Resistance to Reverse Transcriptase Inhibitors: Polymerase Domain
High-resolution structures of HIV-1 RT/RNA:DNA ternary complexes with tenofovir diphosphate and dATP
Kalyan Das; Center for Advanced Biotechnology and Medicine (CABM), and Rutgers University, USA
The HIV -1 RT mutant Q151L shows decreased replication capacity, selective high-level resistance to GS-9148 and hypersusceptibility to tenofovir and zidovudine
Kirsten White; Gilead Sciences, Inc., USA
Mechanisms associated with HIV-1 resistance to acyclovir by the V75I mutation in reverse transcriptase
Matthias Götte; McGill University, Canada
Different evolution and patterns of genotypic resistance profiles in emtricitabine plus tenofovir and lamivudine plus tenofovir containing regimen
Valentina Svicher; University of Rome Tor Vergata, Italy
Lamivudine resistance mutations in HBV reverse transcriptase can be selected even at extremely low levels of viral replication
Carlo Perno; University of Rome Tor Vergata, Italy
Resistance to Integrase Inhibitors
New integrase binding inhibitors acting in synergy with raltegravir
Laurent Thibaut; BioAlliance Pharma, France
Resistance to Reverse Transcriptase Inhibitors: Connection/RNAse H Domains
Mutational analysis of residue Asn348 in HIV-1 reverse transcriptase
Jessica Radzio; University of Pittsburgh, USA
New integrase binding inhibitors acting in synergy with raltegravir
Laurent Thibaut; BioAlliance Pharma, France
New integrase binding inhibitors acting in synergy with raltegravir
Laurent Thibaut; BioAlliance Pharma, France
Protease Inhibitor Resistance
Identification of HIV-1 matrix determinants of fitness compensation in a protease inhibitor resistant virus
Chris Parry; Health Protection Agency, UK
Global Resistance/Epidemiology
Computational models developed without a genotype for resource-poor countries predict response to HIV treatment with 82% accuracy
Andrew Revell; HIV Resistance Response Database Initiative, UK
Drug resistance patterns among HIV-infected children and adults failing Kaletra-based regimens in South Africa
Gillian Hunt; National Institute for Communicable Diseases, South Africa
Protease Inhibitor Resistance
Addition of extended zidovudine to extended nevirapine prophylaxis reduces resistance
in infants who were HIV-infected in utero: the PEPI-Malawi study
Jessica Lidstrom; Johns Hopkins University School of Medicine, USA
Pre-existing low-levels of the K103N HIV-1 RT mutation above a threshold is associated with
virological failure in treatment-naive patients undergoing EFV-containing antiretroviral treatment
Evguenia Svarovskaia; Gilead Sciences, Inc., USA
Bulk sequence-detectable resistance mutations in peripheral RNA following single-dose
nevirapine are associated with poorer treatment responses but do not adequately explain
treatment failure
Jeffrey Johnson; Centers for Disease Control and Prevention, USA
Resistance mutations detected by oligonucleotide ligation assay of HIV-1 DNA at time of
initiation of nevirapine-containing antiretroviral therapy are associated with virologic failure Thor Wagner; University of Washington and Seattle Children?s Hospital, USA
State of the Art Presentation
Myth Versus Reality: Preventing Drug Resistance in Resource-limited Settings Neil Parkin; World Health Organization, Switzerland
|